Smith & Nephew PLC (SNN)
24.01
+0.09
(+0.38%)
USD |
NYSE |
Apr 18, 16:00
24.01
0.00 (0.00%)
After-Hours: 20:00
Smith & Nephew Revenue (TTM): 5.549B for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.549B |
| June 30, 2023 | 5.349B |
| December 31, 2022 | 5.215B |
| June 30, 2022 | 5.213B |
| December 31, 2021 | 5.212B |
| June 30, 2021 | 5.124B |
| December 31, 2020 | 4.56B |
| June 30, 2020 | 4.688B |
| December 31, 2019 | 5.138B |
| Date | Value |
|---|---|
| June 30, 2019 | 4.949B |
| December 31, 2018 | 4.904B |
| June 30, 2018 | 4.869B |
| December 31, 2017 | 4.765B |
| June 30, 2017 | 4.677B |
| December 31, 2016 | 4.669B |
| June 30, 2016 | 4.69B |
| December 31, 2015 | 4.634B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
4.56B
Minimum
Dec 2020
5.549B
Maximum
Dec 2023
5.100B
Average
5.175B
Median
Revenue (TTM) Benchmarks
| AstraZeneca PLC | 45.81B |
| Adaptimmune Therapeutics PLC | 60.28M |
| Biodexa Pharmaceuticals Plc | 0.6446M |
| Verona Pharma PLC | -- |
| NuCana PLC | -- |